NasdaqCM - Nasdaq Real Time Price USD

NLS Pharmaceutics AG (NLSP)

1.7200
-0.0100
(-0.58%)
As of 3:11:22 PM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for NLSP

Recent News: NLSP

View More
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
PR Newswire 7 hours ago
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models
PR Newswire last month
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
ACCESS Newswire last month
NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics CEO Issues Letter to Shareholders
PR Newswire 2 months ago
NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform
PR Newswire 2 months ago
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
PR Newswire 2 months ago
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies
PR Newswire 3 months ago
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics
PR Newswire 3 months ago
NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting
PR Newswire 3 months ago
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence
PR Newswire 3 months ago
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS
PR Newswire 4 months ago
View More

Related Tickers

ENVB Enveric Biosciences, Inc.
1.2150
-9.96%
 
GLTO Galecto, Inc.
3.0300
+0.34%
 
KTTA Pasithea Therapeutics Corp.
0.9166
-6.20%
 
TNFA TNF Pharmaceuticals, Inc.
0.1532
-14.46%
 
PBM Psyence Biomedical Ltd.
4.6319
-12.93%
 
ONCO Onconetix, Inc.
0.0791
-10.11%
 
ABP Abpro Holdings, Inc.
0.2416
-5.13%
 
ARMP Armata Pharmaceuticals, Inc.
2.1450
-4.78%
 
PCSA Processa Pharmaceuticals, Inc.
0.2493
-1.79%
 
QNRX Quoin Pharmaceuticals, Ltd.
8.59
+1.42%